Historically, fungal keratitis was thought to be a suppurative corneal lesion with one or more of the following features: a dry, raised ulcer with crenate (i.e., having a margin with low, rounded ...

Table 4. Comparison of recent controlled trials for treatment of fungal keratitis. Study India [23] India [62] Bangeladesh [63] Medications and dose ...

Background/aims To evaluate the role of early immunosuppressive therapy (IMT) in the management of rheumatoid arthritis (RA)-associated peripheral ulcerative keratitis (PUK). Methods Single-centre, ...

Hyderabad: Light offers a new hope for eye specialists in treating patients with a blinding eye infection associated with contaminated water. In groundbreaking research, ophthalmologists from the city ...

Trehalose expression in mammalian cells is nontoxic. To determine whether trehalose production is toxic to mammalian cells, the viability of cells infected with Ad-OTS and Ad-GFP was compared. 12F ...

Background/aim: There are few clinical series in the literature of infective keratitis in the elderly, even though this age group constitutes a significant proportion of those affected by this ...

Background: Tumour growth is angiogenesis dependent and antiangiogenesis therapy may represent a promising therapeutic option. Aims: To evaluate the inhibitory effect of vasostatin gene mediated by a ...

JMX-0312 protects hamsters from adenoviral lethal infection, study demonstrates. June 5, 2025. No Comments. Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent ...

A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain ...

Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.

What can be done to stop a cold sore early on? Learn more here, along with what causes cold sores in the first place and how to avoid spreading them.

The neurotrophic keratitis treatment market will expand from $1.07 billion in 2024 to $22.6 billion in 2034, fueled by rising aging populations, healthcare expenditure, and eye diseases. Western ...